Korro Bio, INC Schedule 13G passive stakes

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 951,783 shares, representing 6.6% of Korro Bio, Inc.'s common stock.

Point72 Asset Management and affiliated entities have reported a 1.9% beneficial ownership stake in Korro Bio, Inc. as of March 31, 2026.

Lynx1 Capital Management LP and Weston Nichols have reported a 10.7% beneficial ownership stake in Korro Bio, Inc.

The Vanguard Group filed an amended Schedule 13G, indicating zero beneficial ownership in Korro Bio Inc. following an internal realignment effective January 12, 2026.

A group of Venrock entities and individuals have disclosed a 9.9% beneficial ownership stake in Korro Bio, Inc. through a Schedule 13G filing.

Driehaus Capital Management LLC has filed an exit notice, reporting zero beneficial ownership in Korro Bio, Inc. common stock.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 6.37% beneficial ownership stake in Korro Bio, Inc. as of December 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 0.4% in Korro Bio Inc's common stock as of December 31, 2025.

The Vanguard Group reported a 5.19% beneficial ownership stake in Korro Bio Inc, holding 489,639 shares of common stock as of December 31, 2025.

Lynx1 Capital Management LP and Weston Nichols have reported a 7.8% beneficial ownership stake in Korro Bio, Inc. common stock.

Driehaus Capital Management LLC has increased its beneficial ownership in Korro Bio, Inc. to 7.16% of common stock as of September 30, 2025.

Steven A. Cohen's Point72 entities have filed an amended Schedule 13G, disclosing an aggregate beneficial ownership of 8.7% in Korro Bio, Inc. as of June 30, 2025.

Deep Track Capital and affiliates disclose a 2.96% passive beneficial ownership stake in Korro Bio, Inc., holding 277,966 shares of common stock.

AllianceBernstein L.P. has disclosed a 0.1% passive ownership stake in Korro Bio Inc., holding 7,700 shares of common stock.

Citadel Advisors LLC and affiliated entities, including Kenneth Griffin, have filed an amended Schedule 13G disclosing a 3.9% beneficial ownership stake in Korro Bio, Inc. as of December 31, 2024.

Driehaus Capital Management LLC has reported a 5.28% beneficial ownership stake in Korro Bio, Inc. as of December 31, 2024, held in the ordinary course of business.

AllianceBernstein L.P. has disclosed a 7.5% beneficial ownership stake in Korro Bio Inc., holding 705,794 shares of common stock as of December 31, 2024, for investment purposes.